Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | GMNN | O75496 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 2/20 | 0.46 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38319 | 1.00 | LMNA (0.46) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL70127 | 0.88 | LMNA (0.42) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL10669324 | 0.88 | LMNA (0.42) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL16841846 | 0.87 | GMNN (0.37) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL9601533 | 0.84 | KDM4E (0.36) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL7838127 | 0.83 | — | — | |
| SCHEMBL13366525 | 0.83 | — | — | |
| SCHEMBL7826434 | 0.83 | — | — | |
| SCHEMBL20247476 | 0.83 | KDM4E (0.34) | LMNAPMP22TSHRGMNNTP53 | |
| SCHEMBL23601117 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283680-A1 | EMULSIFIERS FOR INVERT EMULSION WELLBORE FLUIDS AND METHODS OF USE THEREOF | M-I L.L.C. | 2017-10-05 | — | — | US | claimed |
| WO-2017173010-A1 | EMULSIFIERS FOR INVERT EMULSION WELLBORE FLUIDS AND METHODS OF USE THEREOF | M-I L.L.C. (US) | 2017-10-05 | — | — | WO | claimed |
| US-20030130135-A1 | Emulsifier for oil-based drilling fluids | CROMPTON CORPORATION | 2003-07-10 | — | — | US | claimed |
| WO-2003042324-A1 | EMULSIFIER FOR OIL-BASED DRILLING FLUIDS | AKZO NOBEL INDUSTRIAL SPECIALTIES INC. (US) | 2003-05-22 | — | — | WO | claimed |
| US-3971728-A | CALCIUM OR MAGNESIUM IONS, 2,5-DI-CARBOXY OR CARBOXYMETHYL TETRAHYDROFURAN OR SALTS | ETHYL CORPORATION (US) | 1976-07-27 | — | — | US | claimed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| CN-114805202-A | Benzene sulfonamide compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-20200165505-A1 | Branched Acid Emulsifier Compositions and Methods of Use | SCHLUMBERGER TECHNOLOGY CORPORATION | 2020-05-28 | — | — | US | disclosed |
| US-10570325-B2 | Branched acid emulsifier compositions and methods of use | M-I L.L.C. (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110809574-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-10030120-B2 | Softener composition which contains tetrahydrofuran derivatives and 1,2-cyclohexane dicarboxylic acid esters | BASF SE (DE) | 2018-07-24 | — | — | US | disclosed |
| EP-0046342-A1 | Detergent compositions and processes of making thereof | THE PROCTER & GAMBLE COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0040882-A1 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0040038-A2 | Granular detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-11-18 | — | — | EP | disclosed |
| EP-0028432-A1 | Granular laundry compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4216215-A | 7[(Furanyl-2-acetamido)-2-acetamido]cephalosporin derivatives | PFIZER INC. (US) | 1980-08-05 | — | — | US | disclosed |
| EP-0008829-A1 | Controlled sudsing detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1980-03-19 | — | — | EP | disclosed |
| US-4137312-A | Epoxy substituted cephalosporin derivatives | PFIZER INC. (US) | 1979-01-30 | — | — | US | disclosed |
| US-3971728-A | CALCIUM OR MAGNESIUM IONS, 2,5-DI-CARBOXY OR CARBOXYMETHYL TETRAHYDROFURAN OR SALTS | ETHYL CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | LMNA 3136/4885PMP22 4364/4885TSHR 4103/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | LMNA 2714/4885PMP22 4602/4885TSHR 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.